Literature DB >> 20678779

Evolution and long term outcome in patients presenting with large demyelinating lesions as their first clinical event.

Pandurang R Wattamwar1, Neeraj N Baheti, Chandrasekharan Kesavadas, Muralidharan Nair, Ashalatha Radhakrishnan.   

Abstract

OBJECTIVES: To describe the long term evolution and outcome of a homogeneous cohort of patients (n=14) with large demyelinating lesions (LDLs) as the first clinical event from a group of idiopathic inflammatory demyelinating diseases of central nervous system.
METHODS: Detailed review of LDLs from December 2002-January 2007 was made. Patients had at least two magnetic resonance imaging (MRI) and minimum follow-up of 2years. The disability was assessed using Estimated Expanded Disability Status Scale (EDSS) and Rappaport Disability Rating Scale (DRS) at onset and last follow-up.
RESULTS: Fourteen consecutive LDL patients (male=7), with mean age 32.7years and mean follow-up of 45.5months were included. Motor deficits (79%) and cognitive symptoms (43%) marked the onset, none had optic neuritis. All except two responded to steroids. Follow-up MRI showed complete resolution in 43%, 57% showing marked reduction in size. On follow-up, 2 relapsed. Mean EDSS and DRS at presentation were 5.93 and 9.07 and at last follow-up were 1.75 and 2.25 (p<0.001).
CONCLUSIONS: Our data suggests that, patients presenting with LDLs as their first clinical event behaves distinctly in their presentation, imaging characteristics, prognosis and long term outcome as compared to MS and ADEM. Albeit significant disability at the onset, these patients show an excellent response to treatment with good functional recovery in long term and rare relapses. Copyright 2010 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20678779     DOI: 10.1016/j.jns.2010.06.030

Source DB:  PubMed          Journal:  J Neurol Sci        ISSN: 0022-510X            Impact factor:   3.181


  12 in total

1.  Acute multiple sclerosis lesion pathology does not predict subsequent clinical course-a biopsy study.

Authors:  Hugh Kearney; Tucker Price; Jane Cryan; Alan Beausang; Seamus Looby; Francesca M Brett; Michael Farrell
Journal:  Ir J Med Sci       Date:  2019-02-15       Impact factor: 1.568

2.  Contralateral recurrence of tumefactive demyelination.

Authors:  Mohammed Nazir Khan; Mihail Guranda; Marco Essig
Journal:  Neuroradiol J       Date:  2015-10-01

3.  Variant of multiple sclerosis with dementia and tumefactive demyelinating brain lesions.

Authors:  Sherifa A Hamed
Journal:  World J Clin Cases       Date:  2015-06-16       Impact factor: 1.337

4.  Fulminant demyelinating diseases.

Authors:  Megan R Rahmlow; Orhun Kantarci
Journal:  Neurohospitalist       Date:  2013-04

5.  Clinical and imaging correlation in patients with pathologically confirmed tumefactive demyelinating lesions.

Authors:  Matthew A Tremblay; Javier E Villanueva-Meyer; Soonmee Cha; Tarik Tihan; Jeffrey M Gelfand
Journal:  J Neurol Sci       Date:  2017-08-10       Impact factor: 3.181

6.  Differential diagnosis of a vanishing brain space occupying lesion in a child.

Authors:  Sherifa A Hamed; Mohamad A Mekkawy; Hosam Abozaid
Journal:  World J Clin Cases       Date:  2015-11-16       Impact factor: 1.337

7.  Chinese Guidelines for the Diagnosis and Management of Tumefactive Demyelinating Lesions of Central Nervous System.

Authors: 
Journal:  Chin Med J (Engl)       Date:  2017-08-05       Impact factor: 2.628

8.  Tumefactive multiple sclerosis in Taiwan.

Authors:  Yi-Chun Kuan; Kai-Chen Wang; Wei-Hsin Yuan; Ching-Piao Tsai
Journal:  PLoS One       Date:  2013-07-18       Impact factor: 3.240

9.  A rare presentation of atypical demyelination: tumefactive multiple sclerosis causing Gerstmann's syndrome.

Authors:  Sharmilee Gnanapavan; Zane Jaunmuktane; Kelly Pegoretti Baruteau; Sakthivel Gnanasambandam; Klaus Schmierer
Journal:  BMC Neurol       Date:  2014-04-02       Impact factor: 2.474

10.  Clinico-radiologic features and therapeutic strategies in tumefactive demyelination: a retrospective analysis of 50 consecutive cases.

Authors:  Aigli G Vakrakou; Dimitrios Tzanetakos; Maria-Eleptheria Evangelopoulos; Theodore Argyrakos; John S Tzartos; Maria Anagnostouli; Elissavet Andreadou; Georgios Koutsis; Georgios Velonakis; Panagiotis Toulas; Elias Gialafos; Antonios Dimitrakopoulos; Erasmia Psimenou; Leonidas Stefanis; Constantinos Kilidireas
Journal:  Ther Adv Neurol Disord       Date:  2021-05-18       Impact factor: 6.570

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.